Cell Therapy Manufacturing Automation Market Growth Outlook Reveals A CAGR Of 14.5% And A Market Value Of $3.58 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Cell Therapy Manufacturing Automation Market Value Expansion And Long-Term Growth Outlook
The cell therapy manufacturing market’s size has expanded swiftly in recent years. It is anticipated to grow from $1.81 billion in 2025 to $2.08 billion by 2026, at a compound annual growth rate (CAGR) of 14.8%. This historical expansion can be attributed to several factors, including heightened cell-processing demand, an increasing need for manufacturing scalability, the rising adoption of automated bioreactors, the expansion of GMP-compliant workflows, and a greater emphasis on production consistency.
The cell therapy manufacturing market is projected to experience swift expansion in the coming years, with its size set to reach $3.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. During the forecast period, this growth is anticipated due to several factors, including the increasing volume of personalized therapies, greater investment in automation platforms, a growing demand for contamination-free workflows, the expansion of large-scale commercial manufacturing, and more stringent regulatory quality requirements. Key trends expected over this period encompass technological advancements in closed systems, process innovations driven by automation, the evolution of integrated workflows, research into real-time analytics, and ongoing research and development in advanced robotics.
Download A Free Sample Report For Comprehensive Market Insights:
#Cell Therapy Manufacturing Automation Market Growth Factors: Which Forces Are Supporting Market Expansion?
The increasing need for gene therapies is anticipated to drive the expansion of the cell therapy manufacturing automation market in the future. Gene therapy is defined as a medical approach where faulty genes are altered or substituted to address or avert illnesses. This rising demand for gene therapy stems from progress in genetic sequencing and diagnostic methods, allowing for accurate identification of disease-causing genes to enable specific treatments. Cell therapy manufacturing automation aids gene therapy by simplifying and standardizing intricate production procedures, guaranteeing uniform quality and scalability. It improves therapeutic development through error reduction, increased efficiency, and the facilitation of dependable, large-scale production of gene-modified cells. As an illustration, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, an increase from five approvals in 2022. Consequently, the expanding demand for gene therapies is fueling the growth of the cell therapy manufacturing automation market.
Cell Therapy Manufacturing Automation Market Segment Performance And Strategic Opportunities
The cell therapy manufacturing automation market covered in this report is segmented –
1) By Component: Hardware, Software, Services
2) By Cell Type: T-Cells, Stem Cells, Natural Killer (NK) Cells, Other Cell Types
3) By Process: Upstream Processing, Downstream Processing, Fill-Finish, Quality Control, Other Processes
4) By End-User: Pharmaceutical And Biotechnology Companies, Research Institutes, Contract Manufacturing Organizations (CMOs), Other End-Users
Subsegments:
1) By Hardware: Automated Bioreactor Systems, Robotic Handling Platforms, Automated Separation Devices, Automated Expansion Units, In Line Quality Analyzers
2) By Software: Electronic Batch Record Software, Manufacturing Execution Software, Workflow Management Software, Data Monitoring Software, Compliance Management Software
3) By Services: Installation Services, Maintenance Services, Validation Services, Training Services, Technical Support Services
Cell Therapy Manufacturing Automation Market Industry Trends: What Changes Are Reshaping Demand?
Leading companies active in the cell therapy manufacturing automation market are concentrating on creating sophisticated solutions, like automated cell therapy systems, to consolidate multi-stage manufacturing processes into unified, validated digital structures that diminish manual involvement and bolster regulatory adherence. An automated cell therapy system denotes a readily available, validated automation offering that electronically connects various cell therapy instruments, such as magnetic separation, centrifugation, electroporation, and incubators, into a single control panel. This integration ensures traceability, repeatability, and cGMP compliance across all production stages. As an illustration, in January 2024, Thermo Fisher Scientific Inc., a US-based life sciences enterprise, unveiled Gibco CTS Cellmation Software, an unprecedented automation solution. This is a unique, off-the-shelf validated software system designed to digitally link instruments from Thermo Fisher’s extensive cell therapy portfolio to automate manufacturing workflows. It incorporates a pre-validated automation infrastructure powered by Emerson’s DeltaV technology, facilitating seamless integration and command over multiple instruments without the need for costly bespoke projects. Additionally, it establishes traceable and repeatable workflows that help guarantee compliance with cGMP and data security regulations, thus reducing manual touchpoints for developers of cell and gene therapies.
Cell Therapy Manufacturing Automation Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the cell therapy manufacturing automation market are Thermo Fisher Scientific Inc., Merck KGaA, Fujifilm Holdings Corporation, Corning Incorporated, Lonza Group AG, Cytiva, WuXi AppTecCo. Ltd., Hitachi High Technologies Corp., CatalentInc., Sartorius AG, Beckman Coulter Life Sciences, Terumo BCT Inc., Miltenyi Biotec, Oxford Biomedica Plc, National Resilience LLC, Minaris Regenerative Medicine LLC, Tulip Interfaces Inc., Invetech Pty Ltd., BlueRock Therapeutics LLC, Cellares Inc., Ascential Medical & Life Sciences, Cell and Gene Therapy Catapult
Access The Complete Cell Therapy Manufacturing Automation Market Report:
Cell Therapy Manufacturing Automation Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the cell therapy manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy manufacturing automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
